Anticoagulation Management Program: Protocols, Monitoring, and DOAC-Era Reversal

Anticoagulants sit on nearly every high-alert medication list precisely because their therapeutic and toxic doses sit close together, dosing is genuinely complex, and the consequences of an error run in both directions: too little anticoagulation and a clot forms; too much and a patient bleeds. A hospital-wide anticoagulation management program is the structure that turns ‘be careful with anticoagulants’ into a defined, auditable set of protocols, monitoring requirements, reversal pathways, and education duties that a surveyor can actually check against.

The regulatory anchor

The Joint Commission has required hospitals to reduce the likelihood of patient harm associated with anticoagulant therapy as a National Patient Safety Goal (NPSG.03.05.01) for over a decade. Effective January 2026, the Joint Commission restructured its Hospital and Critical Access Hospital accreditation programs, retiring the standalone NPSG chapter for those two programs and folding its requirements into a new National Performance Goals (NPG) chapter — the anticoagulation requirement now sits under NPG #14, Effectively Managing Medications, alongside the program’s other high-alert-medication and safe-medication-use expectations. This was a consolidation of existing requirements, not a substantive rewrite: the underlying expectation — standardized practices, defined monitoring, and patient involvement, applied specifically to heparin, low molecular weight heparin, warfarin, and direct oral anticoagulants (DOACs) — is unchanged. Ambulatory, Behavioral Health Care and Human Services, Home Care, Laboratory, Nursing Care Center, and Office-Based Surgery programs continue to carry this requirement under the NPSG chapter rather than NPG for 2026.

One scope carve-out is worth stating up front because it changes what the program needs to cover: the goal explicitly does not apply to routine situations where short-term prophylactic anticoagulation is used to prevent venous thromboembolism around a procedure or hospitalization. The program exists for therapeutic anticoagulation, not routine VTE prophylaxis dosing.

jointcommission.org itself returns a hard block to automated retrieval, so the goal language above is drawn from Joint Commission-published PDF titles and excerpts surfaced through search rather than a direct primary-source fetch — treat the exact requirement language as reported, not verbatim-confirmed, and check the current accreditation manual before citing a specific element as a survey finding.

Program governance

A functioning anticoagulation program is owned by a defined multidisciplinary group — typically an anticoagulation subcommittee reporting to Pharmacy & Therapeutics, with standing representation from pharmacy, hospital medicine or the relevant specialty service (cardiology, neurology, hematology), nursing, and quality/patient safety. Its recurring job is narrower than it sounds: maintain the approved-protocol list, review adverse drug events and near-misses involving anticoagulants, set the monitoring and reversal pathways below, and sign off on formulary changes (a new DOAC, a new reversal agent) before they reach the floor.

Many programs layer a pharmacist-driven anticoagulation or dosing service on top of committee governance — pharmacists managing warfarin dose adjustments and monitoring schedules under a collaborative practice agreement, which the literature associates with better time-in-therapeutic-range performance than unmanaged physician dosing, though the underlying evidence is stronger for warfarin than for DOAC-era management, where dosing is largely fixed rather than titrated.

Approved protocols

The core deliverable a surveyor will ask to see is the standardized, approved protocol set itself — not a description of best practice, but the actual order sets and dosing nomograms in use. At minimum:

• Unfractionated heparin (UFH) infusion nomogram, weight-based, with a defined aPTT or anti-Xa target range and adjustment table.
• Low molecular weight heparin (LMWH) weight-based dosing, with renal-function-adjusted dosing built into the order set rather than left to the prescriber to remember.
• Warfarin initiation and maintenance nomograms, tied to a defined INR monitoring schedule and dose-adjustment logic.
• DOACs (apixaban, rivaroxaban, dabigatran, edoxaban) — indication-specific dosing (the atrial fibrillation dose differs from the VTE treatment dose for several agents), renal-function dosing adjustments or contraindications, and a defined process for verifying the correct dose against indication and renal function at order entry, since DOAC dosing errors are a recurring theme in medication-safety reporting.

Standardizing these as order sets, rather than relying on free-text orders, is the mechanism that actually produces auditable compliance — it is also the piece an EHR build has to keep current as new agents and new indication-specific dosing get FDA-approved.

Baseline and ongoing laboratory monitoring

Monitoring requirements differ meaningfully by agent class, and the program’s job is to make the correct schedule the default rather than something a clinician has to remember:

• Warfarin: baseline INR, PT, and a baseline CBC; ongoing INR per protocol (typically daily during inpatient initiation, tapering to the outpatient monitoring interval at discharge).
• UFH: baseline aPTT, platelet count, and renal function; ongoing aPTT or anti-Xa per the nomogram’s adjustment schedule, plus periodic platelet counts to monitor for heparin-induced thrombocytopenia (HIT).
• LMWH: baseline renal function and platelet count; anti-Xa monitoring is not routine for most patients but is indicated in specific populations — severe renal impairment, pregnancy, extremes of body weight, or where accumulation risk is a concern.
• DOACs: baseline renal function (creatinine clearance), hepatic function, and CBC; DOACs do not have a routine ongoing coagulation monitoring requirement the way warfarin does, but renal function should be rechecked periodically — more frequently as baseline renal function worsens — since renal clearance is a major determinant of drug accumulation, particularly for dabigatran.

DOAC-era reversal

Reversal pathways are the piece that has changed most since the original NPSG language was written, and they need to be a defined, order-set-backed pathway rather than a pharmacist working it out at 2 a.m.:

• Idarucizumab is the specific reversal agent for dabigatran, indicated for patients with life-threatening or uncontrolled bleeding, or who require emergency surgery or an urgent procedure carrying a high bleeding risk.
• Andexanet alfa is the specific reversal agent for the factor Xa inhibitors apixaban and rivaroxaban, dosed (low- or high-dose regimen) based on which agent, the dose taken, and time since the last dose.
• Four-factor prothrombin complex concentrate (4F-PCC) and activated PCC remain in use as non-specific prohemostatic agents — for DOAC reversal where a specific antidote isn’t indicated or available, and as the primary reversal approach for warfarin-associated major bleeding, alongside vitamin K.

Because these agents are expensive, carry their own risks (thrombotic events after andexanet alfa and 4F-PCC use have both been described in the literature), and are frequently needed under time pressure, most programs write a stewardship layer around reversal itself — pharmacy verification of the reversal indication before dispensing, or a required consult, rather than open floor-stock access.

Patient and resident education

The Joint Commission goal language explicitly frames patient/resident involvement as part of the standard, not an optional add-on. A complete program documents, at minimum: written anticoagulant-specific education at initiation (what the drug is for, bleeding precautions, drug and food interactions, what to do if a dose is missed), and — for patients discharged on anticoagulation — a documented discharge education encounter and a defined follow-up plan (an anticoagulation clinic referral, a scheduled INR draw, or documented PCP follow-up within a defined window).

Transitions of care

Anticoagulation is a recurring theme in medication-reconciliation failures specifically because dosing frequently changes across a single admission — a patient bridged from home warfarin to inpatient heparin, then discharged back to warfarin or switched to a DOAC. A defined bridging protocol (when to bridge, when not to) and an explicit anticoagulant reconciliation step at every transition — admission, any inpatient transfer, and discharge — closes a gap that generic medication reconciliation processes can miss if anticoagulants aren’t called out specifically. See medication reconciliation for the underlying process this plugs into.

Program metrics

A program without a measurement layer is a policy document, not a program. Commonly tracked metrics include: percentage of time in therapeutic INR range (TTR) for warfarin patients, anticoagulant-related adverse drug events per the hospital’s ADE surveillance process, DOAC dosing-error rate at order verification, and compliance with the baseline-labs-before-first-dose requirement. See adverse drug event surveillance for how anticoagulant-specific triggers fit into a broader active-surveillance program, and high-alert medication safeguards for where anticoagulants sit within the hospital’s full high-alert medication list.

Frequently asked questions

Does the anticoagulant safety goal apply to prophylactic dosing?

No. The Joint Commission goal explicitly excludes routine short-term prophylactic anticoagulation used to prevent venous thromboembolism around a procedure or hospitalization — it applies to therapeutic anticoagulation.

Do DOACs need the same lab monitoring as warfarin?

No. DOACs do not have a routine ongoing coagulation-monitoring requirement analogous to INR for warfarin. Baseline and periodic renal function monitoring is still required, since renal clearance drives drug accumulation, particularly for dabigatran.

What’s the difference between a reversal agent and a non-specific prohemostatic agent?

Idarucizumab (dabigatran) and andexanet alfa (apixaban, rivaroxaban) are specific antidotes that bind or reverse the target drug directly. Four-factor PCC is a non-specific prohemostatic agent used when a specific antidote isn’t indicated or available, or for warfarin reversal, where it works alongside vitamin K rather than as a direct antidote.

Who typically chairs an anticoagulation stewardship committee?

Structures vary, but the committee is typically a Pharmacy & Therapeutics subcommittee with pharmacy leadership and standing representation from hospital medicine or the relevant specialty service, nursing, and quality/patient safety — not a single-department committee.

This page is written for hospital risk managers, quality directors, and pharmacy/patient-safety leaders building or auditing an anticoagulation management program against current accreditation and medication-safety expectations; it is not clinical dosing guidance for an individual patient. See the patient safety pillar for the broader clinical-risk-and-regulatory-operations landscape this program sits inside.